Pfizer on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5 per cent to US$36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in broader age groups.
The company said it is also on track to deliver 2.3 billion doses of the vaccine, out of the roughly three billion it plans to make this year. Driven by an unprecedented vaccination drive against the COVID-19 pandemic globally, Pfizer's shot has quickly become one of the best-selling products in the company's roughly 172-year history. The company equally splits expenses and profit from the vaccine with its German partner BioNTech.
Other rivals such as Moderna and Johnson & Johnson have faced production snags, helping Pfizer extend its lead in signing supply deals with countries. Pfizer is also rolling out booster doses of the vaccine, while waiting for the outcome of a US regulatory meeting later in the day onThe vaccine brought in sales of US$13 billion in the third quarter. Analysts had expected US$10.88 billion on average, according to seven analysts polled by Refinitiv.
they make money because you sign the indemnity form. while you still lockdown,mask,double jab,suffer from permanent side effect,sudden death 👏👏👏🖕🖕🖕
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »